Gilead Sciences Is on an FDA Approval Hot Streak. Should You Buy the Stock Like There's No Tomorrow?
The company's recent momentum continues unabated.
Gilead Sciences Inc (GILD) News
Latest headlines that mention GILD, newest first · each headline opens the original publisher
- Last price
- $153.07
- Day change
- -2.00%
- Next earnings
- 2026-10-29 AMC
GILD headlines
latest coverageShares of AbbVie, Eli Lilly and Gilead Sciences closed near record highs
Gilead Sciences is branching out beyond its HIV franchise into oncology and immunology therapies.
Since earnings, investors have focused mainly on the biotech company's growth potential with its HIV PrEP medicines.
The company's HIV franchise is stronger than ever, and it's adding a stable of oncology drugs.
A federal appeals court just handed Gilead Sciences (GILD) a legal win that extends into the company's revenue. The decision blocks a group of companies from importing cheaper foreign versions of Gilead's top HIV drug and selling them to American patients. For a company that…
A U.S. appeals court has ruled in favor of Gilead Sciences against companies known as alternative funding programs that import medicines from overseas.
Gilead Sciences (GILD) closed a strong second quarter, and Wall Street noticed. The drugmaker beat sales expectations across its biggest franchises, raised its full-year outlook, and gave analysts fresh reasons to stay bullish heading into the back half of 2026. Bank of America…
Merck & Co.’s Ebola vaccine and an antiviral drug from Gilead Sciences Inc. are set for wider use in eastern Democratic Republic of Congo to blunt the fastest-growing Ebola outbreak on record.
Gilead Sciences narrowly beat sales expectations for its HIV PrEP drug, Yeztugo. Gilead stock slipped, still in a downtrend. The post Gilead Slumps As Long-Term Uncertainty Clouds Massive HIV Beat appeared first on Investor's Business Daily .
Also mentioned with GILD
30d
Headlines that tag both tickers
GILD news alerts
Get an alert by email or push when a new headline mentions GILD.
More news
News headlines aggregated from third-party publishers via public RSS feeds and tagged with the tickers they mention. Frenzy Capital does not publish or endorse the content; clicking a headline opens the original publisher in a new tab.